Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.


Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
11 2021
Historique:
received: 17 05 2021
revised: 27 07 2021
accepted: 09 08 2021
pubmed: 18 8 2021
medline: 27 1 2022
entrez: 17 8 2021
Statut: ppublish

Résumé

Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2 most commonly used RIC regimens, i.v. fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in patients with myelodysplastic syndrome (MDS). Through the Center for International Blood and Marrow Transplant Research (CIBMTR), we identified 1045 MDS patients age ≥60 years who underwent first HSCT with a matched related or matched (8/8) unrelated donor using an RIC regimen. The CIBMTR's definition of RIC was used: a regimen that incorporated an i.v. busulfan total dose ≤7.2 mg/kg or a low-dose melphalan total dose ≤150 mg/m

Identifiants

pubmed: 34403791
pii: S2666-6367(21)01143-X
doi: 10.1016/j.jtct.2021.08.007
pmc: PMC9562611
mid: NIHMS1741964
pii:
doi:

Substances chimiques

Vidarabine FA2DM6879K
Busulfan G1LN9045DK
fludarabine P2K93U8740
Melphalan Q41OR9510P

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

921.e1-921.e10

Subventions

Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

Lancet Haematol. 2018 Apr;5(4):e161-e169
pubmed: 29550384
Biol Blood Marrow Transplant. 2019 Apr;25(4):728-733
pubmed: 30471339
Am J Hematol. 2019 Dec;94(12):1344-1352
pubmed: 31495933
Cancer. 2020 May 15;126(10):2183-2192
pubmed: 32101640
Blood. 2018 Mar 15;131(11):1248-1257
pubmed: 29386198
Biol Blood Marrow Transplant. 2002;8(9):477-85
pubmed: 12374452
Leuk Lymphoma. 2020 Jul;61(7):1678-1687
pubmed: 32133897
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466
pubmed: 28039079
Blood. 2015 Feb 19;125(8):1333-8
pubmed: 25593335
Leukemia. 2007 Dec;21(12):2540-4
pubmed: 17611563
J Clin Oncol. 2016 Jun 1;34(16):1864-71
pubmed: 27044940
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S43-9
pubmed: 26297277
Biol Blood Marrow Transplant. 2013 Sep;19(9):1381-6
pubmed: 23871781
J Clin Oncol. 2014 Sep 1;32(25):2691-8
pubmed: 25092778
Comput Methods Programs Biomed. 2011 Jan;101(1):87-93
pubmed: 20724020
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
Biol Blood Marrow Transplant. 2016 Aug;22(8):1431-1439
pubmed: 27164061
J Clin Oncol. 2010 Jan 20;28(3):405-11
pubmed: 20008642
J Clin Oncol. 2017 Jul 1;35(19):2157-2164
pubmed: 28463633
Cancer. 2017 Jul 15;123(14):2661-2670
pubmed: 28324640
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Biol Blood Marrow Transplant. 2014 Oct;20(10):1618-25
pubmed: 24953017
Intern Med. 2016;55(13):1721-7
pubmed: 27374671
Blood. 2013 Sep 12;122(11):1974-82
pubmed: 23847196
Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
pubmed: 18489989
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):321-326
pubmed: 28641099
J Clin Oncol. 2017 Apr 10;35(11):1154-1161
pubmed: 28380315
Blood Adv. 2018 Aug 28;2(16):2095-2103
pubmed: 30135184
Comput Methods Programs Biomed. 2007 Nov;88(2):95-101
pubmed: 17850917
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S1-S2
pubmed: 18724277
Cancer. 2007 Apr 15;109(8):1536-42
pubmed: 17345612
Blood. 1990 Feb 1;75(3):555-62
pubmed: 2297567
Biol Blood Marrow Transplant. 2017 Dec;23(12):2079-2087
pubmed: 28890406
Leukemia. 2007 Oct;21(10):2109-16
pubmed: 17690701
Bone Marrow Transplant. 2017 Apr;52(4):580-587
pubmed: 27991894
Cancer. 2015 Apr 1;121(7):1048-55
pubmed: 25424330
Bone Marrow Transplant. 2017 Aug;52(8):1107-1112
pubmed: 28319072
Lancet Haematol. 2020 Jan;7(1):e28-e39
pubmed: 31606445

Auteurs

Betül Oran (B)

Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: boran@mdanderson.org.

Kwang Woo Ahn (KW)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.

Caitrin Fretham (C)

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.

Amer Beitinjaneh (A)

Division of Transplantation and Cellular Therapy, University of Miami, Miami, Florida.

Asad Bashey (A)

Division of Transplantation and Cellular Therapy, University of Miami, Miami, Florida.

Attaphol Pawarode (A)

Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Mchigan.

Baldeep Wirk (B)

Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania.

Bart L Scott (BL)

Fred Hutchinson Cancer Research Center, Seattle, Washington.

Bipin N Savani (BN)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Christopher Bredeson (C)

The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Daniel Weisdorf (D)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

David I Marks (DI)

Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.

David Rizzieri (D)

Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.

Edward Copelan (E)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.

Gerhard C Hildebrandt (GC)

Markey Cancer Center, University of Kentucky, Lexington, Kentucky.

Gregory A Hale (GA)

Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.

Hemant S Murthy (HS)

Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.

Hillard M Lazarus (HM)

University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.

Jan Cerny (J)

Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.

Jane L Liesveld (JL)

Department of Medicine, University of Rochester Medical Center, Rochester, New York.

Jean A Yared (JA)

Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.

Jean Yves-Cahn (J)

Department of Hematology, CHU Grenoble Alpes, Grenoble, France.

Jeffrey Szer (J)

Clinical Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Leo F Verdonck (LF)

Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.

Mahmoud Aljurf (M)

Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.

Marjolein van der Poel (M)

Maastricht University Medical Centre, Maastricht, The Netherlands.

Mark Litzow (M)

Division of Hematology and Transplant Center, Mayo Clinic, Rochester, Minnesota.

Matt Kalaycio (M)

Hematology and Medical Oncology, Transplantation Center, Cleveland Clinic, Cleveland, Ohio.

Michael R Grunwald (MR)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.

Miguel Angel Diaz (MA)

Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Mitchell Sabloff (M)

Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Mohamed A Kharfan-Dabaja (MA)

Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.

Navneet S Majhail (NS)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Nosha Farhadfar (N)

Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.

Ran Reshef (R)

Blood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York.

Richard F Olsson (RF)

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.

Robert Peter Gale (RP)

Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.

Ryotaro Nakamura (R)

Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.

Sachiko Seo (S)

Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Saurabh Chhabra (S)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Shahrukh Hashmi (S)

Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Shatha Farhan (S)

Henry Ford Hospital Bone Marrow Transplant Program, Henry Ford Health System, Detroit, Michigan.

Siddhartha Ganguly (S)

Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.

Sunita Nathan (S)

Rush University Medical Center, Chicago, Illinois.

Taiga Nishihori (T)

Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.

Tania Jain (T)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Vaibhav Agrawal (V)

Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.

Ulrike Bacher (U)

Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Uday Popat (U)

Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

Wael Saber (W)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH